Jane M. Pruemer

444 total citations
22 papers, 353 citations indexed

About

Jane M. Pruemer is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane M. Pruemer has authored 22 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Surgery and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane M. Pruemer's work include Cancer Treatment and Pharmacology (6 papers), Nausea and vomiting management (4 papers) and Pain Management and Opioid Use (3 papers). Jane M. Pruemer is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Nausea and vomiting management (4 papers) and Pain Management and Opioid Use (3 papers). Jane M. Pruemer collaborates with scholars based in United States, Canada and Saudi Arabia. Jane M. Pruemer's co-authors include Laurence Green, Michael R. Cohen, Roger W. Anderson, Raymond J. Muller, Jeff J. Guo, Abdul Rahman Jazieh, Zeina Nahleh, Robert J. Cluxton, Zeina Nahleh and Ana L. Hincapie and has published in prestigious journals such as Clinical Chemistry, Annals of Pharmacotherapy and Seminars in Oncology.

In The Last Decade

Jane M. Pruemer

21 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane M. Pruemer United States 10 91 77 75 57 41 22 353
Peter J Gilbar Australia 14 190 2.1× 34 0.4× 47 0.6× 115 2.0× 60 1.5× 61 579
Niesha Griffith United States 10 35 0.4× 44 0.6× 120 1.6× 138 2.4× 40 1.0× 21 402
John Valgus United States 14 88 1.0× 52 0.7× 252 3.4× 174 3.1× 92 2.2× 36 643
F Lombardo United States 9 49 0.5× 62 0.8× 97 1.3× 69 1.2× 30 0.7× 14 379
Elaine Lennan United Kingdom 10 188 2.1× 42 0.5× 45 0.6× 77 1.4× 35 0.9× 25 473
Jill Bates United States 11 75 0.8× 14 0.2× 100 1.3× 43 0.8× 75 1.8× 30 363
Alison Duffy United States 10 63 0.7× 40 0.5× 30 0.4× 38 0.7× 65 1.6× 25 338
Hans-Martin Späth France 9 38 0.4× 64 0.8× 79 1.1× 43 0.8× 23 0.6× 22 306
Sophie Bouvet France 11 37 0.4× 55 0.7× 130 1.7× 73 1.3× 24 0.6× 17 404
Audrey J. Lee United States 12 45 0.5× 81 1.1× 157 2.1× 60 1.1× 17 0.4× 21 496

Countries citing papers authored by Jane M. Pruemer

Since Specialization
Citations

This map shows the geographic impact of Jane M. Pruemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane M. Pruemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane M. Pruemer more than expected).

Fields of papers citing papers by Jane M. Pruemer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane M. Pruemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane M. Pruemer. The network helps show where Jane M. Pruemer may publish in the future.

Co-authorship network of co-authors of Jane M. Pruemer

This figure shows the co-authorship network connecting the top 25 collaborators of Jane M. Pruemer. A scholar is included among the top collaborators of Jane M. Pruemer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane M. Pruemer. Jane M. Pruemer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pruemer, Jane M., et al.. (2020). Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014. Journal of Gynecologic Oncology. 31(4). e52–e52. 32 indexed citations
2.
Eldessouki, Ihab, Mohamed Rahouma, Mohamed Kamel, et al.. (2019). Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014: University of Cincinnati experience. Journal of International Medical Research. 47(12). 6016–6026. 8 indexed citations
3.
Pruemer, Jane M., et al.. (2015). Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy. Journal of Oncology Pharmacy Practice. 22(2). 248–255. 9 indexed citations
4.
Thomas, Hilary, et al.. (2014). The effects of a palliative care program on antidepressant use and continuing maintenance medications in near end-of-life oncology patients (the HEALED study). Journal of Oncology Pharmacy Practice. 21(5). 331–338. 1 indexed citations
5.
Whitmer, Kyra, et al.. (2011). Development of an Outpatient Oncology Symptom Management Clinic. Clinical journal of oncology nursing. 15(2). 175–179. 8 indexed citations
6.
Roddy, Julianna, et al.. (2010). Thromboembolic Events in Patients With Colorectal Cancer Receiving the Combination of Bevacizumab-Based Chemotherapy and Erythropoietin Stimulating Agents. American Journal of Clinical Oncology. 33(1). 36–42. 11 indexed citations
7.
Nahleh, Zeina, et al.. (2010). Melatonin, a Promising Role in Taxane-Related Neuropathy. Clinical Medicine Insights Oncology. 4. 35–41. 29 indexed citations
8.
Pruemer, Jane M.. (2009). Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. American Journal of Health-System Pharmacy. 66(2_Supplement_2). S4–S10. 8 indexed citations
9.
Pruemer, Jane M.. (2006). Treatment of Cancer-Associated Thrombosis: Distinguishing Among Antithrombotic Agents. Seminars in Oncology. 33(2 Suppl 4). 26–39. 4 indexed citations
10.
Pruemer, Jane M., et al.. (2006). Symptom Management Needs of Oncology Outpatients. Journal of Palliative Medicine. 9(3). 628–630. 32 indexed citations
11.
DiPiro, Joseph T., William J. Spruill, William E. Wade, et al.. (2006). Concepts in Clinical Pharmacokinetics, 4th Edition. Annals of Pharmacotherapy. 40(7-8). 1479–1479. 4 indexed citations
12.
Pruemer, Jane M.. (2005). Prevalence, causes, and impact of cancer-associated thrombosis. American Journal of Health-System Pharmacy. 62(22_Supplement_5). S4–S6. 29 indexed citations
13.
Lutomski, Dave M., et al.. (2003). Quality assurance in the prescribing of patient-controlled analgesia and long-acting opioids. American Journal of Health-System Pharmacy. 60(14). 1476–1479. 3 indexed citations
14.
Cohen, Michael R., et al.. (1996). Preventing medication errors in cancer chemotherapy. American Journal of Health-System Pharmacy. 53(7). 737–746. 109 indexed citations
15.
Pruemer, Jane M., et al.. (1996). Impact of an oncology pharmacy residency training program on quality improvement initiatives in an oncology center.. PubMed. 16(1). 59–65. 4 indexed citations
16.
Pruemer, Jane M., et al.. (1991). Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration. American Journal of Health-System Pharmacy. 48(10). 2158–2160.
17.
Pruemer, Jane M., et al.. (1989). Liquid-chromatographic monitoring of cytosine arabinoside and its metabolite, uracil arabinoside, in serum.. Clinical Chemistry. 35(6). 1011–1015. 14 indexed citations
18.
Pruemer, Jane M., et al.. (1989). Liquid-chromatographic monitoring of cytosine arabinoside and its metabolite, uracil arabinoside, in serum.. PubMed. 35(6). 1011–5. 13 indexed citations
19.
Pruemer, Jane M., et al.. (1988). Carboplatin: A New Cisplatin Analog. Drug Intelligence & Clinical Pharmacy. 22(11). 843–849. 21 indexed citations
20.
DiPiro, Joseph T., Robert A. Blouin, & Jane M. Pruemer. (1988). Concepts in clinical pharmacokinetics : a self-instructional course. Medical Entomology and Zoology. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter J Gilbar Breakdown of academic impact, for papers by Niesha Griffith Breakdown of academic impact, for papers by John Valgus Breakdown of academic impact, for papers by F Lombardo Breakdown of academic impact, for papers by Elaine Lennan Breakdown of academic impact, for papers by Jill Bates Breakdown of academic impact, for papers by Alison Duffy Breakdown of academic impact, for papers by Hans-Martin Späth Breakdown of academic impact, for papers by Sophie Bouvet Breakdown of academic impact, for papers by Audrey J. Lee
Rankless by CCL
2026